Aviva’s Acadia Pharmaceuticals ACAD Stock Holding History

Aviva’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$507K	Sell	20,023 -279	-1%	-$6.14K	﹤0.01%	693
2026 Q1	$452K	Buy	20,302 +991	+5%	+$23.7K	﹤0.01%	729
2025 Q4	$516K	Sell	19,311 -942	-5%	-$22.5K	﹤0.01%	730
2025 Q3	$432K	Sell	20,253 -877	-4%	-$20.7K	﹤0.01%	840
2025 Q2	$456K	Sell	21,130 -13,117	-38%	-$244K	﹤0.01%	812
2025 Q1	$569K	Sell	34,247 -1,636	-5%	-$29.7K	﹤0.01%	762
2024 Q4	$658K	Buy	+35,883	New	+$579K	﹤0.01%	657
2021 Q1	–	Sell	-30,740	Closed	-$1.64M	–	939
2020 Q4	$1.64M	Sell	30,740 -24,922	-45%	-$1.24M	0.01%	733
2020 Q3	$2.3M	Buy	55,662 +8,240	+17%	+$356K	0.01%	693
2020 Q2	$2.3M	Buy	+47,422	New	+$2.28M	0.01%	690

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Aviva's ACAD Position: Q2 2026 in Review

Aviva reduced its Acadia Pharmaceuticals (ACAD) stake by 1.4% in Q2 2026, selling an estimated $6.14K and leaving 20,023 shares worth $507K. The position accounts for ﹤0.01% of the portfolio, ranked #693.

Aviva first reported a position in ACAD in Q2 2020 and has held it in 10 quarters since. The position peaked at $2.3M in Q2 2020. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Aviva held 20,023 shares of Acadia Pharmaceuticals worth $507K as of Q2 2026.
Aviva sold 279 Acadia Pharmaceuticals shares in Q2 2026, an estimated $6.14K.
Acadia Pharmaceuticals made up ﹤0.01% of Aviva's portfolio in Q2 2026, its #693 holding.
Aviva first reported a position in Acadia Pharmaceuticals in Q2 2020 and has held it in 10 quarters since.
Aviva's Acadia Pharmaceuticals position peaked at $2.3M in Q2 2020.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.